Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Diagnosis (Berl) ; 7(1): 69-73, 2020 01 28.
Article in English | MEDLINE | ID: mdl-31256063

ABSTRACT

Background Liver abscess is the most common extraintestinal manifestation of Entamoeba histolytica. Clinical manifestations could appear after returning from an endemic area or several years after the exposure. The diagnosis usually requires microbiological confirmation. Case presentation We present a case of a 55-year-old woman diagnosed with Crohn's disease treated with immunosuppressive drugs, who was admitted to the Emergency Service with liver parenchyma abscesses. Computed tomography (CT)-guided puncture showed pus, and both Gram staining and fresh parasite visualization were negative. Hepatic pus bacteriological culture was reported as negative and parasite multiplex polymerase chain reaction (PCR) was performed, being positive for E. histolytica. The same PCR was performed on blood, pleural fluid and stool samples, all of them being positive for E. histolytica. Conclusions Reviewing the clinical history of this patient, it was observed that parasite detection in three stool samples was negative 2 months before the current admission. Due to the lack of sensitivity of the microscopy techniques, we propose to routinely perform parasite detection in stools using molecular techniques, especially in immunocompromised patients.


Subject(s)
Entamoeba histolytica/genetics , Feces/parasitology , Liver Abscess/parasitology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Cefotaxime/administration & dosage , Cefotaxime/therapeutic use , Female , Humans , Immunocompromised Host , Intestinal Diseases, Parasitic/complications , Liver Abscess/diagnostic imaging , Liver Abscess/therapy , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Middle Aged , Paromomycin/administration & dosage , Paromomycin/therapeutic use , Polymerase Chain Reaction/methods , Punctures/methods , Tomography, X-Ray Computed/methods , Treatment Outcome
2.
Intensive Care Med ; 44(9): 1470-1482, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30074052

ABSTRACT

PURPOSE: To determine clinical predictors associated with corticosteroid administration and its association with ICU mortality in critically ill patients with severe influenza pneumonia. METHODS: Secondary analysis of a prospective cohort study of critically ill patients with confirmed influenza pneumonia admitted to 148 ICUs in Spain between June 2009 and April 2014. Patients who received corticosteroid treatment for causes other than viral pneumonia (e.g., refractory septic shock and asthma or chronic obstructive pulmonary disease [COPD] exacerbation) were excluded. Patients with corticosteroid therapy were compared with those without corticosteroid therapy. We use a propensity score (PS) matching analysis to reduce confounding factors. The primary outcome was ICU mortality. Cox proportional hazards and competing risks analysis was performed to assess the impact of corticosteroids on ICU mortality. RESULTS: A total of 1846 patients with primary influenza pneumonia were enrolled. Corticosteroids were administered in 604 (32.7%) patients, with methylprednisolone the most frequently used corticosteroid (578/604 [95.7%]). The median daily dose was equivalent to 80 mg of methylprednisolone (IQR 60-120) for a median duration of 7 days (IQR 5-10). Asthma, COPD, hematological disease, and the need for mechanical ventilation were independently associated with corticosteroid use. Crude ICU mortality was higher in patients who received corticosteroids (27.5%) than in patients who did not receive corticosteroids (18.8%, p < 0.001). After PS matching, corticosteroid use was associated with ICU mortality in the Cox (HR = 1.32 [95% CI 1.08-1.60], p < 0.006) and competing risks analysis (SHR = 1.37 [95% CI 1.12-1.68], p = 0.001). CONCLUSION: Administration of corticosteroids in patients with severe influenza pneumonia is associated with increased ICU mortality, and these agents should not be used as co-adjuvant therapy.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Anti-Infective Agents/therapeutic use , Influenza, Human/drug therapy , Pneumonia, Viral/drug therapy , APACHE , Adult , Critical Care/methods , Critical Illness , Female , Humans , Influenza, Human/complications , Influenza, Human/mortality , Male , Middle Aged , Pneumonia, Viral/complications , Pneumonia, Viral/mortality , Propensity Score , Prospective Studies , Spain/epidemiology , Survival Analysis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...